Skip to main content
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. logo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. — Investor Relations & Filings

Ticker · 1541 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 1,170 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1541

About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

http://www.immuneonco.com

ImmuneOnco Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of immuno-oncology therapies. The company focuses on developing cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and actively eradicate malignant cells. ImmuneOnco is distinguished by its capability to systematically utilize both the innate and adaptive immune systems, positioning it to overcome the limitations of current T-cell based immunotherapies. By leveraging this dual approach, the company aims to address significant unmet medical needs associated with low response rates, drug resistance, and recurrence in various cancer indications.

Recent filings

Filing Released Lang Actions
Proxy Form for the Annual General Meeting to be held on May 28, 2026
Regulatory Filings
2026-04-30 English
NOTICE OF THE ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-30 English
(1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT; (5) 2025 PR
Regulatory Filings
2026-04-30 English
Annual Report 2025
Regulatory Filings
2026-04-29 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March, 2026
Regulatory Filings Classification · 1% confidence The document is a standard FF301 monthly return filed with the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, summarizing movements in registered share capital, issued/Treasury shares, and public float confirmation for the month ending 31 March 2026. It is a recurring regulatory submission rather than an annual or interim report, call transcript, share issue announcement, or dividend notice. It serves as a regulatory filing without fitting into any more specific category, thus it is classified as a Regulatory Filing (RNS).
2026-04-08 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by ImmuneOnco Biopharmaceuticals regarding the dosing of the first patient in a Phase III clinical trial. It contains no financial results, dividend information, management changes, or capital transactions. It is a standalone corporate business development announcement filed on the Hong Kong Exchange with no attachments of a report itself, and does not fit any specialized category (e.g., earnings release, M&A, proxy, etc.). As such, it falls into the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.